MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for
their growth.
PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating
patients with advanced solid tumors or lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
National Institutes of Health Clinical Center (CC)